- $167.80bn
- $219.60bn
- $62.58bn
U.S. STOCKS ON THE MOVE-Zebra Technologies, Pfizer, Cummins
Pfizer edges up after better-than-expected quarterly results
Pfizer Q2 results beat; raises 2026 revenue outlook
Pfizer beats earnings estimates, targets $2.5 billion in additional cost cuts (updated)
Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis
AstraZeneca US M&A idea would ail more than cure
Eli Lilly is pharma’s latest victim of success
Eli Lilly is pharma’s latest victim of success
Bristol Myers raises 2026 forecast as Eliquis, newer medicines power results (updated)
Pfizer's oral drug restores skin pigmentation in late-stage vitiligo trials
Brief: Bristol Myers Q2 Adjusted EPS $2.04 Versus IBES Estimate $1.59
Bristol Myers raises 2026 forecast as Eliquis, newer medicines power results
Brief: European Commission Authorizes Pfizer And Biontech Xfg-Adapted Covid-19 Vaccine In The European Union
Brief: FDA Grants Priority Review For Pfizer's Talzenna Plus Xtandi For The Treatment Of Metastatic Prostate Cancer
Pfizer's prostate cancer drug combination gets US FDA priority review (updated)
Pfizer's prostate cancer drug combination gets FDA priority review
Trump says generic drugs to face no US tariffs for 2 years, then 100% and 200% tariffs later (updated)
Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges
Sanofi sues Pfizer, Moderna over COVID shot technology